Office Action Predictor
Last updated: April 16, 2026
Application No. 18/257,195

Pyrido[2,3-D]Imidazole Derivatives and Their Use As Inhibitors of ITK for the Treatment of Skin Disease

Non-Final OA §112
Filed
Jun 13, 2023
Examiner
SHIM, DAVID M.
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Pfizer INC.
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
2y 10m
To Grant
89%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allow Rate
50 granted / 83 resolved
At TC average
Strong +29% interview lift
Without
With
+28.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
28 currently pending
Career history
111
Total Applications
across all art units

Statute-Specific Performance

§101
0.3%
-39.7% vs TC avg
§103
37.3%
-2.7% vs TC avg
§102
13.5%
-26.5% vs TC avg
§112
34.0%
-6.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 83 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-17 and 22-24 are pending in the application. Claims 14, 16, 17 and 22-24 are rejected. Claims 1-13 and 15 are allowable. Priority This application is a 35 U.S.C. § 371 National Stage Filing of International Application No. PCT/IB2021/061645, filed on December 13, 2021, which claims benefit of Provisional Application No. 63/125,671, filed on December 15, 2020. Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 119(e) as follows: The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of 35 U.S.C. 112(a) or the first paragraph of pre-AIA 35 U.S.C. 112, except for the best mode requirement. See Transco Products, Inc. v. Performance Contracting, Inc., 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994). The disclosure of the prior-filed application, Application No., fails to provide adequate support or enablement in the manner provided by 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph for one or more claims of this application. Instant claims 16, 17 and 22-24 are rejected for containing new matter relative to the originally filed disclosure. The discussion below under 35 U.S.C. 112(a) is incorporated here by reference. For the same reasons, instant claims 16, 17 and 22-24 are not supported by the parent application, i.e., PCT/IB2021/061645, since the parent application contains an analogous disclosure to the instant specification. The main difference is that claims 16, 17 and 22-24 of the instant application were not found or supported in the parent application. For these reasons, the earliest effective filing date of instant claims 16, 17 and 22-24 is considered to be the original filing date of PCT/IB2021/061645, i.e., December 23, 2021. The earliest effective filing date of instant claims 1-15 is December 15, 2020. Information Disclosure Statement The Information Disclosure Statements filed on June 13, 2023 are in compliance with the provisions of 37 CFR 1.97 and 1.98. Accordingly, the Examiner has considered the IDS documents and signed copies of the 1449 forms are attached. Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. § 112(a): (a) IN GENERAL — The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. § 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 16, 17 and 22-24 are rejected under 35 U.S.C. § 112(a) or 35 U.S.C. § 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection. Claims 16 and 22 are drawn towards a compound of formula (I) having the following generic chemical structure: PNG media_image1.png 231 332 media_image1.png Greyscale . The instant disclosure as originally filed, however, does not provide any generic or specific support for the above genus as recited in claims 16 and 22. For instance, the broadest disclosure of the instantly claimed invention is represented by the generic compound of Formula (I) shown below (see e.g., page 3 of instant specification): PNG media_image2.png 234 383 media_image2.png Greyscale . In addition, instant claims 16 and 22 recite “the proviso that R4 is not morpholinyl” which is also not generally supported by the instant disclosure. For example, the instant specification provides embodiments of the instant invention wherein “R4 is N-linked morpholinyl” (see e.g., page 9) but does not otherwise provide support for the claimed proviso. Therefore, instant claims 16 and 22 are deemed to introduce new matter since the claims present a scope that is not fully supported by the original disclosure. Dependent claims 17, 23 and 24 do not correct these issues of new matter and are hence rejected. It is suggested Applicant i) substitute a “=N-” for the “=C-” (i.e., in the position being substituted by “R6”) in the recited formulas and ii) cancel the aforementioned proviso in each claim to overcome these issues of new matter. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. § 112(b): (b) CONCLUSION — The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. § 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 14 is rejected under 35 U.S.C. § 112(b) or 35 U.S.C. § 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. § 112, the applicant), regards as the invention. Claim 14 recites “-OC2H5OCH3” as an alternative for variable R5 and is rejected as indefinite. It appears Applicant intended to recite “-OC2H4OCH3” instead of “-OC2H5OCH3”; therefore, Applicant should amend the claim accordingly. Allowable Subject Matter Claim 1-15 are free of the prior art. However, while claims 1-13 and 15 are allowable, claim 14 is rejected. Conclusion Claims 14, 16, 17 and 22-24 are rejected. Claims 1-13 and 15 are allowable. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAVID M SHIM whose telephone number is 571-270-1205. The examiner can normally be reached Monday - Friday, 8 am - 4 pm EST. The examiner can also be reached via email (david.shim@uspto.gov) once an Authorization for Internet Communications form PTO/SB/439 has been filed by Applicant. See MPEP § 502.03 for details. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JOSEPH K MCKANE can be reached on 571-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /D.M.S./Examiner, Art Unit 1626 /JOSEPH K MCKANE/Supervisory Patent Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Jun 13, 2023
Application Filed
Sep 25, 2025
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12590092
ANTIVIRAL AGENTS AND USES THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12576075
Combination Therapies For Treating Cancer
2y 5m to grant Granted Mar 17, 2026
Patent 12577223
PROCESSES FOR PREPARING 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE
2y 5m to grant Granted Mar 17, 2026
Patent 12559462
Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto
2y 5m to grant Granted Feb 24, 2026
Patent 12552786
INHIBITORS OF AV ß6 INTEGRIN
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
89%
With Interview (+28.7%)
2y 10m
Median Time to Grant
Low
PTA Risk
Based on 83 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month